SCHEMBL4641476

SCHEMBL4641476

COc1cc(/C=C/C=C/C(=O)NCCCN2CCN(CCCNC(=O)/C=C/C=C/c3cc(OC)c(OC)c(OC)c3)CC2)cc(OC)c1OC

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 3/20 0.64
HPGD P15428 1/20 0.64
DRD2 P14416 8/20 0.61
DRD3 P35462 8/20 0.61
HTR1A P08908 2/20 0.58
HTR2C P28335 2/20 0.58
HTR2A P28223 1/20 0.58
SLC6A4 P31645 1/20 0.58
HTR7 P34969 1/20 0.58
HTR6 P50406 1/20 0.58
SLC29A1 Q99808 1/20 0.57
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4640429 0.86 HTR1A (0.64) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL10532933 0.85 HTR1A (0.65) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL10532931 0.85 HTR1A (0.65) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL10531022 0.84 HTR1A (0.67) KDM4EALDH1A1HPGDDRD2DRD3
SCHEMBL4641656 0.82 HTR1A (0.61) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL5574112 0.82 KDM4E (0.60) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL5574117 0.82 KDM4E (0.60) KDM4EALDH1A1HPGDHTR1AHTR2C
SCHEMBL10734790 0.82 KDM4E (0.58) KDM4EALDH1A1HPGDDRD2DRD3
Hydrochloric Acid SCHEMBL5570637 0.81 KDM4E (0.59) KDM4EALDH1A1HPGDHTR1AHTR2C
Hydrochloric Acid SCHEMBL5570632 0.81 KDM4E (0.59) KDM4EALDH1A1HPGDHTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0934924-B1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2008-08-13 EP disclosed
US-6576642-B2 Inhibitors of the production of Ig E antibodies, antiallergens KOWA CO., LTD. (JP) 2003-06-10 US disclosed
US-20010039279-A1 Diamide compounds and compositions containing the same KOWA CO., LTD. (JP) 2001-11-08 US disclosed
US-6297283-B1 EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS KOWA CO., LTD. (JP) 2001-10-02 US disclosed
EP-0934924-A1 NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039279-A1 Diamide compounds and compositions containing the same HRH4, HRH2, HRH1 KDM4E 721/4885ALDH1A1 1240/4885HPGD 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.